-
Published on Aug 12, 2016
Stem
cell research group ReNeuron Group Plc (LON:RENE) has taken a step
forward in its bid to develop a new stroke disability treatment.
ReNeuron has had the results of the first human clinical trial of its CTX stem cell therapy drug candidate published in respected medical journal The Lancet.
Chief executive Michael Hunt said: "It's important for us as a business involved in stem cell research and development to expose the data, both pre-clinical and clinical, to scrutiny and peer review.
"The best way to do this is to publish it in quality scientific and medical journals like The Lancet."
http://www.4-traders.com/RENEURON-GROUP-PLC-4005458/
No comments:
Post a Comment